Introduction We examine the role of brain apolipoprotein B (apoB) as a putative marker of
early tau pathology and cognitive decline. Methods Cerebrospinal fluid (CSF) samples from …

Background: Plasma-based biomarkers would be potential biomarkers for early diagnosis of
Alzheimer's disease (AD) because they are more available and cost-effective than …

Background We previously identified four Alzheimer's disease (AD) subgroups with
increasingly higher cerebrospinal fluid (CSF) levels of tau phosphorylated at threonine 181 …

Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early
changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels …

Background We aimed to investigate the tau biomarker discrepancies of Alzheimer's
disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal …

Recent advances in biomarkers provide the possibility of early or preclinical diagnosis of
Alzheimer's pathology. Currently, decreased levels of Aβ-42 and increased levels of tau …

Blood‐based phosphorylated tau (Ptau) 181 and 217 biomarkers are sensitive and specific
for Alzheimer's disease. In this racial/ethnically diverse cohort study, participants were …

Alzheimer's disease (AD) pathology is estimated to develop many years before detectable
cognitive decline. Fluid and imaging biomarkers may identify people in early symptomatic …

Plasma biomarkers related to amyloid, tau, and neurodegeneration (ATN) show great
promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by …

Objective To examine whether apolipoprotein B (ApoB), apolipoprotein A‐1 (ApoA1), or their
ratio (ApoB/A1) were associated with early changes in cerebrospinal fluid (CSF) biomarkers …